arrow_back Back Filing freshness 10-Q FY 2026 SEC EDGAR

PRECISION BIOSCIENCES INC

DTIL
$7.51 ▲ +0.11 (+1.49%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
9 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

PRECISION BIOSCIENCES INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $96.3M
Dividend Yield
Revenue Growth -50.1%
Op. Margin -152.2%
ROIC -44.7%
FCF / Share $-5.13
Trailing P/E
Price / Book 2.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$34.26M
↓ -50.1%
Net Income Profit after all expenses
$-45.72M
↓ -738.0%
Operating Margin Operating profit as % of sales
-152.2%
↓ -299.6% 0th
FCF / Share Free cash flow per share
$-5.13
↑ +40.0%
Long-Term Debt Long-term obligations
$22.22M
↑ +796.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
12
Financial Health
17
Cash Quality
75

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 36 quarters